tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

AMRX Stock Latest News

Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
The FlyAmneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
3d ago
AMRX
Amneal gets FDA approval for memantine/donepezil extended-release capsules
PremiumThe Fly
Amneal gets FDA approval for memantine/donepezil extended-release capsules
1M ago
AMRX
Amneal receives FDA tentative approval for ANDA for rifaximin
PremiumThe Fly
Amneal receives FDA tentative approval for ANDA for rifaximin
1M ago
AMRX
Amneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61c
PremiumThe Fly
Amneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61c
1M ago
AMRX
Amneal Pharmaceuticals Maintains Transparency with SEC Filing
PremiumCompany Announcements
Amneal Pharmaceuticals Maintains Transparency with SEC Filing
1M ago
8K
AMRX
Amneal Pharmaceuticals director Patel sells 62,590 class A shares
PremiumThe FlyAmneal Pharmaceuticals director Patel sells 62,590 class A shares
1M ago
AMRX
Appeals court sides with Amneal over Teva in inhaler patent fight
Premium
The Fly
Appeals court sides with Amneal over Teva in inhaler patent fight
2M ago
AMRX
TEVA
Amneal resubmits DHE autoinjector NDA, gets FDA approval for exenatide
Premium
The Fly
Amneal resubmits DHE autoinjector NDA, gets FDA approval for exenatide
3M ago
AMRX
Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
PremiumThe Fly
Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
3M ago
AMRX
Amneal Pharmaceuticals Reports Q3 2024 Financial Results
PremiumCompany Announcements
Amneal Pharmaceuticals Reports Q3 2024 Financial Results
4M ago
AMRX
Amneal Pharmaceuticals reports Q3 adjusted EPS 16c, consensus 13c
PremiumThe Fly
Amneal Pharmaceuticals reports Q3 adjusted EPS 16c, consensus 13c
4M ago
AMRX
Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
PremiumThe Fly
Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
4M ago
AMRX
AMRX Earnings this Week: How Will it Perform?
PremiumPre-EarningsAMRX Earnings this Week: How Will it Perform?
4M ago
AMRX
Amneal Pharmaceuticals receives FDA approval of Pyridostigmine Bromide NDA
Premium
The Fly
Amneal Pharmaceuticals receives FDA approval of Pyridostigmine Bromide NDA
4M ago
AMRX
Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
Premium
The Fly
Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
5M ago
AMRX
Amneal and Metsera Partner to Target Obesity Market
PremiumCompany Announcements
Amneal and Metsera Partner to Target Obesity Market
5M ago
8K
AMRX
Amneal Pharmaceuticals and Metsera to codevelop weight loss medicines
PremiumThe Fly
Amneal Pharmaceuticals and Metsera to codevelop weight loss medicines
5M ago
AMRX
Amneal Pharmaceuticals debuts Crexont extended-release for Parkinson’s treatment
PremiumThe Fly
Amneal Pharmaceuticals debuts Crexont extended-release for Parkinson’s treatment
5M ago
AMRX
Amneal Pharmaceuticals upgraded to Neutral from Underweight at JPMorgan
PremiumThe Fly
Amneal Pharmaceuticals upgraded to Neutral from Underweight at JPMorgan
6M ago
AMRX
Amneal Pharmaceuticals announces FDA approval of BORUZU
PremiumThe FlyAmneal Pharmaceuticals announces FDA approval of BORUZU
6M ago
AMRX
Amneal Pharmaceuticals receives FDA approval for Propofol Injectable Emulsion
Premium
The Fly
Amneal Pharmaceuticals receives FDA approval for Propofol Injectable Emulsion
6M ago
AMRX
Amneal Pharmaceuticals price target raised to $10 from $8 at Barclays
Premium
The Fly
Amneal Pharmaceuticals price target raised to $10 from $8 at Barclays
6M ago
AMRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >